

Relapsed Acute Myeloid Leukemia Drug Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/R91D53E794DBEN.html>

Date: March 2022

Pages: 117

Price: US\$ 3,250.00 (Single User License)

ID: R91D53E794DBEN

Abstracts

This report contains market size and forecasts of Relapsed Acute Myeloid Leukemia Drug in global, including the following market information:

Global Relapsed Acute Myeloid Leukemia Drug Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global Relapsed Acute Myeloid Leukemia Drug Market Sales, 2017-2022, 2023-2028, (K Pcs)

Global top five Relapsed Acute Myeloid Leukemia Drug companies in 2021 (%)

The global Relapsed Acute Myeloid Leukemia Drug market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

aNK Program Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Relapsed Acute Myeloid Leukemia Drug include 4SC AG, AbbVie Inc., Actinium Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Amgen Inc., Arog Pharmaceuticals, Inc., Array BioPharma Inc., Astellas Pharma Inc. and Astex Pharmaceuticals, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Relapsed Acute Myeloid Leukemia Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Relapsed Acute Myeloid Leukemia Drug Market, by Type, 2017-2022, 2023-2028 (\$ Millions) & (K Pcs)

Global Relapsed Acute Myeloid Leukemia Drug Market Segment Percentages, by Type, 2021 (%)

aNK Program

AT-9283

BI-836858

Binimetinib

BL-8040

Others

Global Relapsed Acute Myeloid Leukemia Drug Market, by Application, 2017-2022, 2023-2028 (\$ Millions) & (K Pcs)

Global Relapsed Acute Myeloid Leukemia Drug Market Segment Percentages, by Application, 2021 (%)

Clinic

Hospital

Others

Global Relapsed Acute Myeloid Leukemia Drug Market, By Region and Country,
2017-2022, 2023-2028 (\$ Millions) & (K Pcs)

Global Relapsed Acute Myeloid Leukemia Drug Market Segment Percentages, By
Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Relapsed Acute Myeloid Leukemia Drug revenues in global market, 2017-2022 (Estimated), (\$ millions)

Key companies Relapsed Acute Myeloid Leukemia Drug revenues share in global market, 2021 (%)

Key companies Relapsed Acute Myeloid Leukemia Drug sales in global market,

2017-2022 (Estimated), (K Pcs)

Key companies Relapsed Acute Myeloid Leukemia Drug sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

4SC AG

AbbVie Inc.

Actinium Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Amgen Inc.

Arog Pharmaceuticals, Inc.

Array BioPharma Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

BioLineRx, Ltd.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Celgene Corporation

Cornerstone Pharmaceuticals, Inc.

CTI BioPharma Corp.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Relapsed Acute Myeloid Leukemia Drug Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Relapsed Acute Myeloid Leukemia Drug Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG OVERALL MARKET SIZE

- 2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size: 2021 VS 2028
- 2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue, Prospects & Forecasts: 2017-2028
- 2.3 Global Relapsed Acute Myeloid Leukemia Drug Sales: 2017-2028

3 COMPANY LANDSCAPE

- 3.1 Top Relapsed Acute Myeloid Leukemia Drug Players in Global Market
- 3.2 Top Global Relapsed Acute Myeloid Leukemia Drug Companies Ranked by Revenue
- 3.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Companies
- 3.4 Global Relapsed Acute Myeloid Leukemia Drug Sales by Companies
- 3.5 Global Relapsed Acute Myeloid Leukemia Drug Price by Manufacturer (2017-2022)
- 3.6 Top 3 and Top 5 Relapsed Acute Myeloid Leukemia Drug Companies in Global Market, by Revenue in 2021
- 3.7 Global Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Type
- 3.8 Tier 1, Tier 2 and Tier 3 Relapsed Acute Myeloid Leukemia Drug Players in Global Market
 - 3.8.1 List of Global Tier 1 Relapsed Acute Myeloid Leukemia Drug Companies
 - 3.8.2 List of Global Tier 2 and Tier 3 Relapsed Acute Myeloid Leukemia Drug

Companies

4 SIGHTS BY PRODUCT

4.1 Overview

4.1.1 By Type - Global Relapsed Acute Myeloid Leukemia Drug Market Size Markets, 2021 & 2028

4.1.2 aNK Program

4.1.3 AT-9283

4.1.4 BI-836858

4.1.5 Binimetinib

4.1.6 BL-8040

4.1.7 Others

4.2 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue & Forecasts

4.2.1 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2022

4.2.2 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2023-2028

4.2.3 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028

4.3 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales & Forecasts

4.3.1 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2022

4.3.2 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2023-2028

4.3.3 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028

4.4 By Type - Global Relapsed Acute Myeloid Leukemia Drug Price (Manufacturers Selling Prices), 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Relapsed Acute Myeloid Leukemia Drug Market Size, 2021 & 2028

5.1.2 Clinic

5.1.3 Hospital

5.1.4 Others

5.2 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue & Forecasts

5.2.1 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2022

5.2.2 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue,

2023-2028

5.2.3 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028

5.3 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales & Forecasts

5.3.1 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2022

5.3.2 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2023-2028

5.3.3 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028

5.4 By Application - Global Relapsed Acute Myeloid Leukemia Drug Price (Manufacturers Selling Prices), 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Relapsed Acute Myeloid Leukemia Drug Market Size, 2021 & 2028

6.2 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue & Forecasts

6.2.1 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2022

6.2.2 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2023-2028

6.2.3 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028

6.3 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales & Forecasts

6.3.1 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2022

6.3.2 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2023-2028

6.3.3 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028

6.4 North America

6.4.1 By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2028

6.4.2 By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2028

6.4.3 US Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.4.4 Canada Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.4.5 Mexico Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.5 Europe

6.5.1 By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue,

2017-2028

6.5.2 By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2028

6.5.3 Germany Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.5.4 France Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.5.5 U.K. Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.5.6 Italy Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.5.7 Russia Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.5.8 Nordic Countries Relapsed Acute Myeloid Leukemia Drug Market Size,

2017-2028

6.5.9 Benelux Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.6 Asia

6.6.1 By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2028

6.6.2 By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2028

6.6.3 China Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.6.4 Japan Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.6.5 South Korea Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.6.6 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.6.7 India Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.7 South America

6.7.1 By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2028

6.7.2 By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2028

6.7.3 Brazil Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.7.4 Argentina Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.8 Middle East & Africa

6.8.1 By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2028

6.8.2 By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales, 2017-2028

6.8.3 Turkey Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.8.4 Israel Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.8.5 Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

6.8.6 UAE Relapsed Acute Myeloid Leukemia Drug Market Size, 2017-2028

7 MANUFACTURERS & BRANDS PROFILES

7.1 4SC AG

7.1.1 4SC AG Corporate Summary

- 7.1.2 4SC AG Business Overview
- 7.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
- 7.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
- 7.1.5 4SC AG Key News
- 7.2 AbbVie Inc.
 - 7.2.1 AbbVie Inc. Corporate Summary
 - 7.2.2 AbbVie Inc. Business Overview
 - 7.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
 - 7.2.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
 - 7.2.5 AbbVie Inc. Key News
- 7.3 Actinium Pharmaceuticals, Inc.
 - 7.3.1 Actinium Pharmaceuticals, Inc. Corporate Summary
 - 7.3.2 Actinium Pharmaceuticals, Inc. Business Overview
 - 7.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
 - 7.3.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
 - 7.3.5 Actinium Pharmaceuticals, Inc. Key News
- 7.4 Agios Pharmaceuticals, Inc.
 - 7.4.1 Agios Pharmaceuticals, Inc. Corporate Summary
 - 7.4.2 Agios Pharmaceuticals, Inc. Business Overview
 - 7.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
 - 7.4.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
 - 7.4.5 Agios Pharmaceuticals, Inc. Key News
- 7.5 Amgen Inc.
 - 7.5.1 Amgen Inc. Corporate Summary
 - 7.5.2 Amgen Inc. Business Overview
 - 7.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
 - 7.5.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)
 - 7.5.5 Amgen Inc. Key News
- 7.6 Arog Pharmaceuticals, Inc.
 - 7.6.1 Arog Pharmaceuticals, Inc. Corporate Summary
 - 7.6.2 Arog Pharmaceuticals, Inc. Business Overview
 - 7.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major

Product Offerings

7.6.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.6.5 Arog Pharmaceuticals, Inc. Key News

7.7 Array BioPharma Inc.

7.7.1 Array BioPharma Inc. Corporate Summary

7.7.2 Array BioPharma Inc. Business Overview

7.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.7.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.7.5 Array BioPharma Inc. Key News

7.8 Astellas Pharma Inc.

7.8.1 Astellas Pharma Inc. Corporate Summary

7.8.2 Astellas Pharma Inc. Business Overview

7.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.8.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.8.5 Astellas Pharma Inc. Key News

7.9 Astex Pharmaceuticals, Inc.

7.9.1 Astex Pharmaceuticals, Inc. Corporate Summary

7.9.2 Astex Pharmaceuticals, Inc. Business Overview

7.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.9.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.9.5 Astex Pharmaceuticals, Inc. Key News

7.10 AstraZeneca Plc

7.10.1 AstraZeneca Plc Corporate Summary

7.10.2 AstraZeneca Plc Business Overview

7.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.10.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.10.5 AstraZeneca Plc Key News

7.11 AVEO Pharmaceuticals, Inc.

7.11.1 AVEO Pharmaceuticals, Inc. Corporate Summary

7.11.2 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Business

Overview

7.11.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.11.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.11.5 AVEO Pharmaceuticals, Inc. Key News

7.12 BioLineRx, Ltd.

7.12.1 BioLineRx, Ltd. Corporate Summary

7.12.2 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Business Overview

7.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.12.5 BioLineRx, Ltd. Key News

7.13 Boehringer Ingelheim GmbH

7.13.1 Boehringer Ingelheim GmbH Corporate Summary

7.13.2 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Business Overview

7.13.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.13.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.13.5 Boehringer Ingelheim GmbH Key News

7.14 Boston Biomedical, Inc.

7.14.1 Boston Biomedical, Inc. Corporate Summary

7.14.2 Boston Biomedical, Inc. Business Overview

7.14.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.14.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.14.5 Boston Biomedical, Inc. Key News

7.15 Bristol-Myers Squibb Company

7.15.1 Bristol-Myers Squibb Company Corporate Summary

7.15.2 Bristol-Myers Squibb Company Business Overview

7.15.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.15.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.15.5 Bristol-Myers Squibb Company Key News

7.16 Calithera Biosciences, Inc.

7.16.1 Calithera Biosciences, Inc. Corporate Summary

7.16.2 Calithera Biosciences, Inc. Business Overview

7.16.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.16.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.16.5 Calithera Biosciences, Inc. Key News

7.17 Celgene Corporation

7.17.1 Celgene Corporation Corporate Summary

7.17.2 Celgene Corporation Business Overview

7.17.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.17.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.17.5 Celgene Corporation Key News

7.18 Cornerstone Pharmaceuticals, Inc.

7.18.1 Cornerstone Pharmaceuticals, Inc. Corporate Summary

7.18.2 Cornerstone Pharmaceuticals, Inc. Business Overview

7.18.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.18.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.18.5 Cornerstone Pharmaceuticals, Inc. Key News

7.19 CTI BioPharma Corp.

7.19.1 CTI BioPharma Corp. Corporate Summary

7.19.2 CTI BioPharma Corp. Business Overview

7.19.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings

7.19.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2017-2022)

7.19.5 CTI BioPharma Corp. Key News

8 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG PRODUCTION CAPACITY, ANALYSIS

8.1 Global Relapsed Acute Myeloid Leukemia Drug Production Capacity, 2017-2028

8.2 Relapsed Acute Myeloid Leukemia Drug Production Capacity of Key Manufacturers in Global Market

8.3 Global Relapsed Acute Myeloid Leukemia Drug Production by Region

9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

9.1 Market Opportunities & Trends

9.2 Market Drivers

9.3 Market Restraints

10 RELAPSED ACUTE MYELOID LEUKEMIA DRUG SUPPLY CHAIN ANALYSIS

10.1 Relapsed Acute Myeloid Leukemia Drug Industry Value Chain

10.2 Relapsed Acute Myeloid Leukemia Drug Upstream Market

10.3 Relapsed Acute Myeloid Leukemia Drug Downstream and Clients

10.4 Marketing Channels Analysis

10.4.1 Marketing Channels

10.4.2 Relapsed Acute Myeloid Leukemia Drug Distributors and Sales Agents in Global

11 CONCLUSION

12 APPENDIX

12.1 Note

12.2 Examples of Clients

12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Relapsed Acute Myeloid Leukemia Drug in Global Market

Table 2. Top Relapsed Acute Myeloid Leukemia Drug Players in Global Market, Ranking by Revenue (2021)

Table 3. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Companies, (US\$, Mn), 2017-2022

Table 4. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Companies, 2017-2022

Table 5. Global Relapsed Acute Myeloid Leukemia Drug Sales by Companies, (K Pcs), 2017-2022

Table 6. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Companies, 2017-2022

Table 7. Key Manufacturers Relapsed Acute Myeloid Leukemia Drug Price (2017-2022) & (USD/Pcs)

Table 8. Global Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Type

Table 9. List of Global Tier 1 Relapsed Acute Myeloid Leukemia Drug Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Relapsed Acute Myeloid Leukemia Drug Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US\$, Mn), 2017-2022

Table 13. By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US\$, Mn), 2023-2028

Table 14. By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2017-2022

Table 15. By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2023-2028

Table 16. By Application – Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2021 & 2028

Table 17. By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US\$, Mn), 2017-2022

Table 18. By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US\$, Mn), 2023-2028

Table 19. By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales (K

Pcs), 2017-2022

Table 20. By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2023-2028

Table 21. By Region – Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2021 VS 2028

Table 22. By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US\$, Mn), 2017-2022

Table 23. By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US\$, Mn), 2023-2028

Table 24. By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2017-2022

Table 25. By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2023-2028

Table 26. By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2017-2022

Table 29. By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2023-2028

Table 30. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2022

Table 31. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2023-2028

Table 32. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2017-2022

Table 33. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2023-2028

Table 34. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2022

Table 35. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2023-2028

Table 36. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2017-2022

Table 37. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2023-2028

Table 38. By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2022

Table 39. By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2023-2028

Table 40. By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2017-2022

Table 41. By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2023-2028

Table 42. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2022

Table 43. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2023-2028

Table 44. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2017-2022

Table 45. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2023-2028

Table 46. 4SC AG Corporate Summary

Table 47. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 48. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 49. AbbVie Inc. Corporate Summary

Table 50. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 51. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 52. Actinium Pharmaceuticals, Inc. Corporate Summary

Table 53. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 54. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 55. Agios Pharmaceuticals, Inc. Corporate Summary

Table 56. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 57. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 58. Amgen Inc. Corporate Summary

Table 59. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 60. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 61. Arog Pharmaceuticals, Inc. Corporate Summary

Table 62. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 63. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 64. Array BioPharma Inc. Corporate Summary

Table 65. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 66. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 67. Astellas Pharma Inc. Corporate Summary

Table 68. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 69. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 70. Astex Pharmaceuticals, Inc. Corporate Summary

Table 71. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 72. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 73. AstraZeneca Plc Corporate Summary

Table 74. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 75. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 76. AVEO Pharmaceuticals, Inc. Corporate Summary

Table 77. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 78. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 79. BioLineRx, Ltd. Corporate Summary

Table 80. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 81. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 82. Boehringer Ingelheim GmbH Corporate Summary

Table 83. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 84. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 85. Boston Biomedical, Inc. Corporate Summary

Table 86. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 87. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K

Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 88. Bristol-Myers Squibb Company Corporate Summary

Table 89. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 90. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 91. Calithera Biosciences, Inc. Corporate Summary

Table 92. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 93. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 94. Celgene Corporation Corporate Summary

Table 95. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 96. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 97. Cornerstone Pharmaceuticals, Inc. Corporate Summary

Table 98. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 99. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 100. CTI BioPharma Corp. Corporate Summary

Table 101. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Offerings

Table 102. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US\$, Mn) and Average Price (USD/Pcs) (2017-2022)

Table 103. Relapsed Acute Myeloid Leukemia Drug Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)

Table 104. Global Relapsed Acute Myeloid Leukemia Drug Capacity Market Share of Key Manufacturers, 2020-2022

Table 105. Global Relapsed Acute Myeloid Leukemia Drug Production by Region, 2017-2022 (K Pcs)

Table 106. Global Relapsed Acute Myeloid Leukemia Drug Production by Region, 2023-2028 (K Pcs)

Table 107. Relapsed Acute Myeloid Leukemia Drug Market Opportunities & Trends in Global Market

Table 108. Relapsed Acute Myeloid Leukemia Drug Market Drivers in Global Market

Table 109. Relapsed Acute Myeloid Leukemia Drug Market Restraints in Global Market

Table 110. Relapsed Acute Myeloid Leukemia Drug Raw Materials

Table 111. Relapsed Acute Myeloid Leukemia Drug Raw Materials Suppliers in Global Market

Table 112. Typical Relapsed Acute Myeloid Leukemia Drug Downstream

Table 113. Relapsed Acute Myeloid Leukemia Drug Downstream Clients in Global Market

Table 114. Relapsed Acute Myeloid Leukemia Drug Distributors and Sales Agents in Global Market

List Of Figures

LIST OF FIGURES

- Figure 1. Relapsed Acute Myeloid Leukemia Drug Segment by Type
- Figure 2. Relapsed Acute Myeloid Leukemia Drug Segment by Application
- Figure 3. Global Relapsed Acute Myeloid Leukemia Drug Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Relapsed Acute Myeloid Leukemia Drug Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2017-2028 (US\$, Mn)
- Figure 7. Relapsed Acute Myeloid Leukemia Drug Sales in Global Market: 2017-2028 (K Pcs)
- Figure 8. The Top 3 and 5 Players Market Share by Relapsed Acute Myeloid Leukemia Drug Revenue in 2021
- Figure 9. By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
- Figure 10. By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
- Figure 11. By Type - Global Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs), 2017-2028
- Figure 12. By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
- Figure 13. By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
- Figure 14. By Application - Global Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs), 2017-2028
- Figure 15. By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
- Figure 16. By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
- Figure 17. By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028
- Figure 18. By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028
- Figure 19. US Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028
- Figure 20. Canada Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

2017-2028

Figure 21. Mexico Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 22. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028

Figure 23. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028

Figure 24. Germany Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 25. France Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 26. U.K. Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 27. Italy Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 28. Russia Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 29. Nordic Countries Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 30. Benelux Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 31. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028

Figure 32. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028

Figure 33. China Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 34. Japan Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 35. South Korea Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 36. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 37. India Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 38. By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028

Figure 39. By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028

Figure 40. Brazil Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 41. Argentina Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 42. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2017-2028

Figure 43. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2017-2028

Figure 44. Turkey Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 45. Israel Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 46. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 47. UAE Relapsed Acute Myeloid Leukemia Drug Revenue, (US\$, Mn), 2017-2028

Figure 48. Global Relapsed Acute Myeloid Leukemia Drug Production Capacity (K Pcs), 2017-2028

Figure 49. The Percentage of Production Relapsed Acute Myeloid Leukemia Drug by Region, 2021 VS 2028

Figure 50. Relapsed Acute Myeloid Leukemia Drug Industry Value Chain

Figure 51. Marketing Channels

I would like to order

Product name: Relapsed Acute Myeloid Leukemia Drug Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/R91D53E794DBEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R91D53E794DBEN.html>